The plant floor is still the bottleneck in cell and gene therapy

by Priya NairClinical and Regulatory Correspondent, HMND

The past week did not bring a clean breakthrough so much as a familiar reminder: enthusiasm for cell and gene therapy still outruns the evidence burden, the analytical toolset, and the reality of the plant floor. The frustration for senior engineering and R and D teams is simple and well earned: the science may be compelling, but the process still has to prove, again and again, that it can make the same product with the same meaning for regulators and the same chance of benefit for patients.

The frustration is real

For people living inside this work, the annoyance is not abstract. It is the gap between a therapy that looks elegant in a deck and a process that behaves like a weather system once it hits real material, real timing, and real operators. In CAR T and other autologous products, the starting material is variable by design, the workflow is multistep, and the vein to vein window is short, which leaves very little room for drift.

That is why the manufacturing conversation keeps circling back to the same hard limit. Viral vector programs still wrestle with capsid separation, vector stability, infectivity loss, and raw material variability while trying to hold quality steady at larger scale. The field keeps talking about scale up as if it were a question of bigger tanks or more runs. In practice, it is a question of control, repeatability, and what the process does when biology refuses to stay tidy.

Every change pulls on validation and filing work

This is where adoption slows down even when the science looks strong. In advanced therapies, a process change is rarely just a process change. A new filter, a different reagent source, a shift in culture conditions, or a new closed system can pull on comparability studies, assay bridging, stability questions, and regulatory filing work.

That burden is not bureaucratic theater. It is the only way to show that what changed on the floor did not change the product in ways that matter clinically. The problem is that many teams only feel that weight late, after the process is already close to transfer or scale up. By then, every improvement comes with a long tail of validation, documentation, and regional filing strategy that can slow launch and drain the same people needed to stabilize production.

Fill finish remains a pressure point

Fill finish is one of the least glamorous parts of the chain and one of the easiest places to lose control. These products often have narrow handling windows, fragile cells or vectors, and tight constraints on purity, identity, sterility, and potency testing. If the process is still being tuned when the product reaches fill finish, that instability gets carried forward instead of absorbed.

This is where the mismatch between expectation and reality becomes most visible. The market hears about platform manufacturing and faster access. The plant floor sees batch specific handling, short shelf life, limited material for in process checks, and release decisions that have to be made quickly, sometimes before the full picture is available. That is not a failure of ambition. It is what happens when development assumes manufacturing can be handled after the clinical story is already in motion.

What failure looks like when manufacturing is treated as downstream

Failure in this field is usually not dramatic. It looks like runs that fail because the starting material was weaker than expected, the culture step did not behave the same way twice, or the analytical data did not support release in time. It looks like a process that works in one suite but does not hold when moved to another site, another operator group, or another supplier chain.

It also looks like the obvious regulatory question landing at the worst possible time: if a process change altered a critical attribute, how do we know the clinical product is still the same product? When manufacturing is treated as something to solve after proof of concept, the result is usually not speed. It is rework, deviation review, and a slow reconciliation between what the biology promised and what the data can defend.

Why the field keeps stalling at the same place

The deeper problem is that cell and gene therapy still depends on platforms that are not fully platformed. The industry wants repeatability, but it starts with highly variable biology. It wants speed, but potency, sterility, and identity testing are often too slow for the clinical schedule. It wants scale, but many processes are constrained by scarce vector supply, limited analytical tools, and complex manufacturing capacity bottlenecks.

So the reader frustration is justified. The public keeps hearing that the next wave of advanced therapies is ready, yet the manufacturing story still reads like a series of controlled exceptions. Until teams design for process control, comparability, and release from the beginning, the gap between promise and practice will stay open.

Anyone who has sat through deviation review knows the lesson is usually plain by the time it arrives. If the plant floor was an afterthought in development, it will eventually make itself known, usually at the least convenient moment. If others are seeing the same pattern, it is worth comparing notes before the next batch teaches the lesson again.